文献速递心力衰竭与心肌病

达格列净在射血分数轻度降低或保留的心衰患者中临床获益的时间:DELIVER 随机临床试验预设二次分析

Time to Clinical Benefit of Dapagliflozin in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Secondary Analysis of the DELIVER Randomized Clinical Trial.
PubMed 文献 · JAMA Cardiol · 2022-01-01

DELIVER 试验预设二次分析纳入 6263 例射血分数>40% 的症状性心衰患者,随机接受达格列净 10 mg 每日一次或安慰剂。中位随访 2.3 年,主要复合终点发生 1122 例。心衰恶化事件 16 天首次且持续显著。

要点

  • 达格列净在射血分数轻度降低或保留心衰中约 2 周内即显效。
  • 主要终点 13 天首次名义显著,15 天起持续显著。
  • 心衰恶化事件 16 天首次且持续显著,30 天及以后各时点获益持续。

核心结论

  • 达格列净在射血分数轻度降低或保留的心衰患者中早期且持续降低临床事件,治疗开始 2 周内即见统计学显著下降。

研究设计与样本

  • DELIVER 为全球 3 期临床试验,将射血分数轻度降低或保留的心衰患者随机分配至达格列净或匹配安慰剂。
  • 本分析为预设二次分析,纳入 20 个国家 350 个中心共 6263 例患者,女性 2747 例(43.9%),平均(SD)年龄 71.7(9.6)岁。
  • 入组标准包括症状性心衰、左心室射血分数>40%、利钠肽水平升高及结构性心脏病证据。
  • 干预为达格列净 10 mg 每日一次或匹配安慰剂;中位(IQR)随访 2.3(1.7-2.8)年。

主要发现

  • 随访期间主要终点事件 1122 例,发生率每 100 患者年 8.7(95%CI 8.2-9.2)。
  • 主要终点和心衰恶化事件的显著获益在 30 天、90 天、6 个月、1 年、2 年及最终随访时持续(主要终点:HR 0.82,95%CI 0.73-0.92;心衰恶化事件:HR 0.79,95%CI 0.69-0.91)。

临床怎么用

  • 对射血分数轻度降低或保留的心衰患者,达格列净 10 mg 每日一次可在约 2 周内观察到临床事件下降。
  • 临床决策中可将达格列净作为该人群早期事件预防的组成部分,获益在 30 天及长期随访中持续。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Dapagliflozin was recently shown to reduce cardiovascular death or worsening heart failure (HF) events in patients with HF with mildly reduced or preserved ejection fraction in the Dapagliflozin Evaluation to Improve the Lives of Patients With Preserved Ejection Fraction Heart Failure (DELIVER) trial. OBJECTIVE: To evaluate the time course of benefits of dapagliflozin on clinically relevant outcomes in this population. DESIGN, SETTING, AND PARTICIPANTS: The DELIVER trial was a global phase 3 clinical trial that randomized patients with HF with mildly reduced or preserved ejection fraction to dapagliflozin or matching placebo. Inclusion criteria included symptomatic HF, left ventricular ejection fraction greater than 40%, elevated natriuretic peptide levels, and evidence of structural heart disease. In this prespecified secondary analysis of the DELIVER trial, to examine the timeline to onset of clinical benefit with dapagliflozin, hazard ratios (HR) and 95% CIs were iteratively estimated for the primary composite end point and worsening HF events alone with truncated data at every day postrandomization. Time to first and sustained statistical significance of dapagliflozin for these end points were then examined. Participants were enrolled from August 2018 to December 2020, and for this secondary analysis, data were analyzed from April to September 2022. INTERVENTIONS: Dapagliflozin, 10 mg, once daily or matching placebo. MAIN OUTCOMES AND MEASURES: The primary outcome was time to first occurrence of cardiovascular death or worsening HF (hospitalization for HF or urgent HF visit requiring intravenous HF therapies). RESULTS: Overall, 6263 patients were randomized across 350 centers in 20 countries. Of 6263 included patients, 2747 (43.9%) were women, and the mean (SD) age was 71.7 (9.6) years. During a median (IQR) of 2.3 (1.7-2.8) years' follow-up, 1122 primary end point events occurred, with an incidence rate per 100 patient-years of 8.7 (95% CI, 8.2-9.2). Time to first nominal statistical significance for the primary end point was 13 days (HR, 0.45; 95% CI, 0.20-0.99; P = .046), and significance was sustained from day 15 onwards. First and sustained statistical significance was reached for worsening HF events (HR, 0.45; 95% CI, 0.21-0.96; P = .04) by day 16 after randomization. Significant benefits for the primary end point and worsening HF events were sustained at 30 days, 90 days, 6 months, 1 year, 2 years, and final follow-up (primary end point: HR, 0.82; 95% CI, 0.73-0.92; worsening HF events: HR, 0.79; 95% CI, 0.69-0.91). CONCLUSIONS AND RELEVANCE: In the DELIVER trial, dapagliflozin led to early and sustained reductions in clinical events in patients with HF with mildly reduced or preserved ejection fraction with statistically significant reductions observed within 2 weeks of treatment initiation. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03619213.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Vaduganathan, Claggett, Jhund, et al. Time to Clinical Benefit of Dapagliflozin in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Secondary Analysis of the DELIVER Randomized Clinical Trial. JAMA Cardiol. 2022. PMID: 36190011. doi:10.1001/jamacardio.2022.3750

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。